Verapamil's calcium channel-independent effect on ischemia-reperfusion injury in patients with acute myocardial infarction

To explore the non-calcium channel-dependent effect of verapamil on ischemia-reperfusion injury in patients with acute myocardial infarction

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000031891

Enrollment

Unknown

Registered

2020-04-13

Start date

2019-01-01

Completion date

Unknown

Last updated

2020-04-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute myocardial infarction

Interventions

Verapamil group:20mg Verapamil

Placebo group:Warm drinking water

Healthy People Group (not randomization):Warm drinking water

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Aged 40 to 90 years old; 3) Never take any type of CCB antihypertensive drugs; 4) Patients with acute myocardial infarction and emergency PCI; 5) The last chest pain does not exceed 18h; 6) Sign informed consent.

Exclusion criteria

Exclusion criteria: 1) Hemodynamically unstable; 2) Merging other life-threatening diseases; 3) Those with infectious diseases; 4) Calcium channel blockers in any dosage form are currently being used; 5) History of past mental and psychological diseases; 6) Pregnancy or lactation, or planned pregnancy (if female); 7) After organ transplantation; 8) Other serious diseases, such as malignant tumors, which the researchers think are not suitable for participating in this research; 9) Currently participating in other studies as subjects.

Design outcomes

Primary

Measure	Time frame
IL-6;TNF-alpha;IL-1beta;SOD;MDA;MIF;PGI2;PGE2;TXA2;CK-MB;cTnT;	—

Countries

China

Contacts

Public ContactShi Ganggang

Shantou University Medical College

ggshi@stu.edu.cn+86 13902734172

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026